Differential gene expression between human schwannoma and control Schwann cells by Hanemann, C. O. et al.
ht
tp
://
do
c.
re
ro
.c
h
Differential gene expression between human 
schwannoma and control Schwann cells
C. O. Hanemann*, B. Bartelt-Kirbach†, R. Diebold†, K. Kämpchen†, S. Langmesser‡ and T. Utermark§
*Clinical Neurobiology, Peninsula Medical School, Peymouth, UK, †Center for Clinical Research, Department of  Heurology, 
University Ulm, Ulm, Germany, ‡Institut de Biochimie, Université de Fribourg, Fribourg, Switzerland, and §Department of  
Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA
The NF2 gene encodes the tumour suppressor protein
merlin. The mutation of  a single allele of  this gene causes
the autosomal dominantly inherited disease neuroﬁbro-
matosis type 2 (NF2), which is characterized mainly by
vestibular schwannoma carrying a second hit mutation.
Complete lack of  merlin is also found in spontaneous
schwannomas and meningiomas. As the events leading to
schwannoma development are largely unknown we inves-
tigated the differences in gene expression between schw-
annoma cells from NF2 patients and normal human
primary Schwann cells by cDNA array analysis. We iden-
tiﬁed 41 genes whose expression levels differed by more
than factor 2. Most of  these clones were corroborated by
real-time reverse transcription polymerase chain reaction
analysis. By this method a total of  seven genes with
increased and seven genes with decreased mRNA levels in
schwannoma compared with normal Schwann cells could
be identiﬁed. Regulated clones, some of  which not been
described in Schwann cells earlier, included matrix metal-
loproteinase’s, growth factors, growth factor receptors
and tyrosine kinases.
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Introduction
The NF2 gene is located on chromosome 22q12.2 and
codes for the tumour suppressor protein merlin/schwan-
nomin [1,2]. Merlin belongs to the protein 4.1 super fam-
ily and shows high homology to the ERM (ezrin, radixin,
moesin) proteins of  cytoskeleton-cell membrane linkers. A
germ line mutation in one allele of  the NF2 gene causes
the autosomal dominantly inherited cancer predisposition
syndrome neuroﬁbromatosis type 2 (NF2). This syndrome
is characterized by bilateral vestibular schwannomas and
in addition, benign tumours of  the nervous system such as
meningiomas and ependymoma’s are also common to this
disease. Bi-allelic mutations of  the NF2 gene have been
identiﬁed in not only all of  the NF2-related tumours, but
also in 100% of  spontaneous schwannomas and 50–60%
of  spontaneous meningiomas [3,4]. Consequently, Merlin
is undetectable in the tumour samples [5–7]. Recent ﬁnd-
ings in primary human Schwann and schwannoma cells
indicate that loss of  merlin impairs contact-dependent
growth arrest as well as the formation of  stable cadherin-
containing cell–cell junctions [8] (Utermark et al. submit-
ted) and causes alterations in the adhesion to the extra cel-
lular matrix [9].
Classical Merlin knockout mice develop various kinds of
tumours, most of  them highly malignant, but no schwan-
nomas [10].
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Up to date several interaction partners of  merlin have
been identiﬁed, mostly using either mouse or rat model
systems. Among those binding partners betaII-spectrin
[11], CD44 [12], magicin [13], HRS (hepatocyte growth
factor-regulated tyrosine kinase substrate) [14], paxillin
[15], NHERF (EPB-50) [16] and PIKE-L [17] to merlin
were also found in human cell line settings.
Concerning cell-type speciﬁcity the association of  mer-
lin with CD44, betaII-spectrin, HRS and paxillin was
shown in rat Schwann or schwannoma cells. We were
unable to detect the expression of, for example, magican in
human Schwann cells (Hanemann et al. unpubl. data). It
is, however, likely that interaction partners of  merlin will
be identiﬁed in human Schwann cells in the future.
Merlin has been demonstrated to be involved in intra-
cellular signalling in different cell types. Merlin is
involved in the Rac/Pak signalling pathway [18–22].
Rac1 activation hardly detectable in merlin –/– mouse
ﬁbroblast [23] is clearly upregulated in primary human
schwannoma cells [19]. Also, merlin increases the p53
stability by inhibiting the Mdm2-mediated degradation
of  p53 [24].
In order to identify genes involved in schwannoma
development, we performed cDNA array analyses and
subsequent real-time reverse transcription polymerase
chain reaction (RT-PCR) on primary cell cultures of
human NF2 schwannomas, presenting a deﬁned geno-
type, compared with human Schwann cells of  healthy
donors. By means of  this approach we were able to identify
a number of  differentially regulated genes, some of  which
so far were not known to be expressed in human Schwann
cells.
Materials and methods
Cell culture
Normal human Schwann and schwannoma cells were
isolated and cultured as previously described [25,26].
Peripheral nerves were obtained from surgical patients
not carrying any disease predisposing to a peripheral neu-
ropathy after informed consent. Schwannoma were kindly
provided by NF2 patients after informed consent. Diagno-
sis of  NF2 was based on clinical criteria deﬁned by the NIH
Consensus Conference on Neuroﬁbromatosis [27]. At the
time of  RNA extraction cell cultures were intended to be
grown to an equal conﬂuency of  about 80%.
RNA extraction
Total RNA was extracted from cell cultures homogenized
by QiaShredder (Qiagen, Hilden, Germany) using the
method described by Chomczynski and Sacchi [28], fol-
lowed by DNase I treatment. RNA for real-time PCR anal-
ysis was also extracted using the RNeasy spin columns
(Qiagen, Hilden, Germany) according to the manufactur-
ers instructions with DNase I treatment on the columns.
RNA integrity was checked on a 0.8% agarose gel stained
with ethidium bromide.
CDNA array analysis
Hybridization of  cDNA to the Atlas Human 1.2 Array (BD
Biosciences, San Jose, CA, USA) was performed according
to the manufacturer’s instructions with the following
exceptions. For probe synthesis with the Clontech Probe
Synthesis Kit, MMLV reverse transcriptase was replaced
by SuperScriptTM (Invitrogen, Carlsbad, CA, USA). Probes
were puriﬁed by ChromaSpin columns (BD Biosciences,
San Jose, CA, USA) and [32P]dATP labelling efﬁciency
was measured by a beta counter. Hybridized array mem-
branes were exposed to a phosphor intensifying screen
(Molecular Dynamics, Freiburg, Germany) and scanned at
three time points (days 1, 3 and 8). Data analysis was car-
ried out using the ImageQuant software (Amersham
Pharmacia Biotech, Freiburg, Germany). The signal
intensity between arrays was normalized against the
housekeeping genes on the respective array as well as total
array counts as suggested by the manufacturer. We used
two different established methods  of  normalization  to
add  additional  security.  For signiﬁcance, a doubling of
the signal intensity was requested. The experiment was
repeated twice, using RNA of  different normal human
Schwann and schwannoma cells.
Real-time RT-PCR analysis
cDNA was synthesized with the First strand cDNA synthe-
sis kit for RT-PCR (AMV) (Roche Applied Science, Man-
nheim, Germany) using a ﬁxed volume of  the eluted RNA
(8.2 μl) and random hexamer primers.
For real-time PCR analysis, a LightCycler (Roche
Applied Science, Mannheim) with software LightCycler 3
Run, version 5.32, and LightCycler 3 Data Analysis, ver-
sion 3.5.28, was applied using SYBR green (LightCycler
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DNA Master SYBR Green I, Roche Applied Science, Man-
nheim, Germany) or the QuantiTect SYBR Green PCR Kit
(Qiagen, Hilden, Germany), according to the respective
manufacturers instructions. After the LightCycler run,
the real-time PCR products were checked for unwanted
by-products on a 2% agarose gel stained with ethidium
bromide, and runs with by-products were optimized until
only the wanted product was ampliﬁed.
Primers and PCR conditions used are listed in Table 1.
For the relative quantiﬁcation of  the cDNA amounts we
used the standard curve method and normalization to the
housekeeping gene HPRT (hypoxanthine guanine phos-
phoribosyltransferase). For each primer pair serial dilu-
tions of  the cDNA ranging from 1:10, 1:25 and 1:50–
1:100 were performed. The Crossing Points for the indi-
vidual sample are automatically determined by the Second
Derivate Maximum Method (Roche Applied Science).
Using the linear regression line the relative concentration
Table 1. Primer sequences, product length and annealing temperature used for real-time polymerase chain reaction
Gene Upstream primer Downstream primer Size (bp) Annealing (°C)
APP 5′-ctcccgctggtactttgatgtg-3′ 5′-gggcaagaggttcctgggtagt-3′ 164 60
CBL-B 5′-ccacgattatgggctcagtt-3′ 5′-gaaatgggctccacttttca-3′ 178 60
CCND1 5′-ccgtccatgcggaagatc-3′ 5′-atggccagcgggaagac-3′ 86 60
CD19 (Paradisi et al.) 5′-ctccacactctggctgtcct-3′ 5′-cagcagccagtgccatagta-3′ 277 55
CDKN1A 5′-caggggacagcagaggaaga-3′ 5′-gcttcctgtgggcggatta-3′ 201 60
CRHR1 5′-agccatcgtgctcacctact-3′ 5′-ggggccctggtagatgtagt-3′ 181 60
CTNNA1 5′-gctgctctccaacacagtcac-3′ 5′-cgctcgtcctgcttctg-3′ 235 55
FLT1 5′-ctttaaccttgaacacagctca3′ 5′-gtaacagtgatgttaggtgacgtaa-3′ 231 60
GRLF1 5′-aaaatcaacgaccgggagca-3′ 5′-gggccagaagcagatggaga-3′ 171 60
GRO2 5′-cacactcaagaatgggcaga-3′ 5′-aaacacattaggcgcaatcc-3′ 217 60
HMGA 5′-tgggttccatttttcctctg-3′ 5′-aacaggaggcaatgaggatg-3′ 133 60
IGFBP1 5′-ccctgaaagcccagagagca-3′ 5′-ggcagggctccttccatttt-3′ 170 60
IL11 5′-gccctgtggggacatgaact-3′ 5′-gcagggaatccaggttgtgg-3′ 239 60
INHA up1 5′-tctgagcccgaggaagagga-3′ 5′-gctgcgtgtatgctgggatg-3′ 156 55
up2 5′-gaaggtggggaccctggagt-3′ 5′-gctgcgtgtatgctgggatg-3′ 225 55
ITGA6 5′-cagttgagttgtgttgccaa-3′ 5′-gaaggtttagcaactcccg-3′ 250 55
ITGB1 5′-gtggttgctggaattgttctta-3′ 5′-agtgttgtgggatttgcac-3′ 219 55
ITGB4 5′-atagagtcccaggatggagga-3′ 5′-gtggtggagatgctgctgta-3′ 97 55
JNK2 5′-cgccactccttctcagtcttc-3′ 5′-ccatcaactcccaagcatttc-3′ 200 55
MAG 5′-tgccatcgtctgctacattaccc-3′ 5′-caggcgcctctcgctctcg-3′ 151 60
MAP2K3 5′-gaccttcatcaccattggag-3′ 5′-cgtagaaggtgacagtgtag-3′ 232 60
MAP3K11 5′-gctgctgtgggaactgctga-3′ 5′-ctgcaggatggaggcgaagt-3′ 193 60
MCP1 5′-gtgttcaagtcttcggagtt-3′ 5′-caataggaagatctcagtgc-3′ 187 60
MMP11 5′-aggtactggcatggggacga-3′ 5′-gccttggctgctgttgtgtg-3′ 212 60
MMP14 5′-cactgcctacgagaggaagg-3′ 5′-ttggggtactcgctatccac-3′ 246 60
MMP17 5′-ctccaaggccgaccataacg-3′ 5′-cgtggacagccactgcaaac-3′ 179 60
NR2F1 (Moré et al. 2003) 5′-gctgcctcaaagccatcgtg-3′ 5′-aaggtctaggagcactggatgga-3′ 318 62
PDGFA 5′-gctgctgcaacacgagcagt-3′ 5′-ccggattcaggcttgtggtc-3′ 168 60
PEP1 5′-attctccaaccaatgatgtgc-3′ 5′-ggattggagagacagcgaag-3′ 283 55
PGF 5′-gttcagcccatcctgtgtct-3′ 5′-cttcatcttctcccgcagag-3′ 199 60
PRNP 5′-tccgagccagtcgctgacag-3′ 5′-cctgaggtgggtagcggttg-3′ 225 60
PTMA 5′-cgggaatgctaatgaggaaa-3′ 5′-tcggtcttctgcttcttggt-3′ 213 60
P75 5′-gtgggacagagtctgggtgt-3′ 5′-aaggaggggaggtgatagga-3′ 199 63
RAC1 5′-gccgattgccgatgtgtt-3′ 5′-ctcggatcgcttcgtcaaa-3′ 307 55
SLC6A6 5′-gctgagcttgtcccctggaa-3′ 5′-aggagcatggcgaatggaaa-3′ 165 60
TIE1 5′-tggcatggagtgcactgtga-3′ 5′-aatggccttggtggacagga-3′ 189 60
TIMP 5′-cacccacagacggccttct-3′ 5′-aggcttggaaccctttatacatctt-3′ 136 60
TNK1 5′-cctccagggccctctactcc-3′ 5′-tctgtggcatccctcacacaa-3′ 135 55
VEGF 5′-cacccatggcagaaggagga-3′ 5′-actccaggccctcgtcattg-3′ 201 60
ZNF161 5′-tcgacacaagctctcccattca-3′ 5′-ggtcaggccttgagaagccttt-3′ 167 60
HPRT (Erovic et al. 2003) 5′-gccagactttgttggatttg-3′ 5′-ctctcatcttaggctttgtattttg-3′ 141 55–62
TBP (Bieche et al. 1999) 5′-cacgaaccacggcactgatt-3′ 5′-ttttcttgctgccagtctggac-3′ 89 55–62
G6PDH (Radonic et al. 2004) 5′-atcgaccactacctgggcaa-3′ 5′-ttctgcatcacgtcccgga-3′ 191 55–62
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of  the unknown sample is calculated following the nor-
malization with the regression line of  the housekeeping
gene. As a second method we used the approach described
by Ramakers et al. [29], which determines the PCR efﬁ-
ciency from the increase of  absolute ﬂuorescence within
the window of  linearity of  the PCR reaction by linear
regression.  The  amount  of  starting  template  then  fol-
lows from  the  intercept  of  this  linear  regression  line.
The computer program called LinRegPCR for easy use of
the method is available upon request, email to
bioinfo@amc.uva.nl. For normalization of  our data to three
housekeeping genes, we used the GeNorm VBA applet for
MS Excel [30] (available at http://medgen.ugent.be/
%7Ejvdesomp/genorm/). It determines the most stable
housekeeping gene in a given set of  four tested housekeep-
ing genes. The three most stable ones are then selected for
sample normalization. For this, the applet calculates a nor-
malization factor for each sample based on the geometric
mean of  the three housekeeping genes. The three house-
keeping genes used were HPRT (hypoxanthine guanine
phosphoribosyltransferase), TBP (TATA-box binding pro-
tein) and G6PDH (glucose-6-phosphate dehydrogenase).
Western blot
Cell pellets were lysed using 100 μl of  denaturing lysis
buffer [1% TritonX-100; 20 mM Tris-HCl (pH 7.5);
150 mM NaCl; 1 mM MgCl2; 2 mM EDTA; 10% Glycerol;
0.1% SDS; 1% Sodium deoxycholate; 1:500 small peptide
inhibitor mix (Sigma, St. Louis, MO, USA); 1:100 100 mM
PMSF stock (Sigma) (in 100% ethanol) per 4 × 105 cells].
Protein concentrations were determined with a detergent
compatible protein assay (Biorad, Hercules, CA, USA) and
proteins were separated by SDS-Page on 8% polyacryla-
mide gels. Coomassie blue staining (Biorad) and subse-
quent analysis of  the relative lane intensities by use of  the
GelPro Analyser software (Media Cybernetics, Working-
ham, UK) was used to allow more accurate loading ratios
between a particular pair of  normal Schwann cell and
schwannoma cell lysate. Proteins were transferred to
either nitrocellulose (Hybond ECL, Amersham Pharmacia
Biotech), or polyvinylidene ﬂuoride (Immobilon P 1500,
Millipore, Billerica, MA, USA) membrane by wet transfer.
Primary antibodies used were polyclonal anti-RhoGDI
(1:500; Santa Cruz, Santa Cruz, CA, USA, A20), poly-
clonal anti-nerve growth factor (NGF) receptor (1:1000;
Sigma N3908). Overnight incubation was followed by
incubation with corresponding secondary antibody
marked with horseradishperoxidase (HRP) and ECL
detection. After revelation, membranes were subjected to
a Colloidal Gold Total Protein staining (Biorad) according
to the manufacturer’s protocol. Lane band densities were
compared between schwannoma and Schwann cell total
protein lysates, thus ascertaining not only equal loading,
but also equivalent transfer of  the proteins onto the
membrane.
Thus, in total controls of  equal loading and transfer
were assured at four different levels: (i) equivalent number
of  cells per volume of  lysis buffer; (ii) protein assay based
on Lowry; (iii) Coomassie blue stain on gels; and (iv) col-
loidal gold stain of  membrane.
Results cDNA array analysis
The Atlas Human 1.2 cDNA Array was used to determine
differential expression between primary human schwan-
noma and normal Schwann cells. Within the total of
1176 genes dotted on the cDNA array, 41 were found to be
either up- or downregulated by a factor of  ≥2 (Table 2,
gene bank accession numbers are given in italics). House
keeping genes on the array for normalization were chosen
as it has been published numerous times that they are not
regulated. However, we also used total array signal for
normalization in addition as suggested as an alternative
by the manufacturer. Thirty genes were regulated to sim-
ilar extent using both methods for normalization, 11
genes were regulated ≥2 using one of  the normalization
methods. All genes regulated by applying combined meth-
ods (total array signal and housekeeping signal) of  nor-
malization were certainly also regulated also using just
one method of  normalization.
Real-time RT-PCR analysis
Thirty-six of  the 41 genes identiﬁed by array analysis were
further investigated by real-time RT-PCR analysis with at
least three different pairs of  schwannoma/normal
Schwann cell cDNA. The genes omitted from real-time
PCR analysis were CD44 which has earlier been investi-
gated by Sherman et al. [31], HSP27 which has been
investigated by Utermark et al. [32], GATA2 (GATA-bind-
ing protein 2), SLC5A2 (solute carrier family 5, member
2) and FLT1 [vascular endothelial growth factor (VEGF)
receptor 1] which gave no reproducible RT-PCR results.
Table 3  summarizes the results of  the real-time RT-PCR
analysis. Fourteen genes of  this set showed a reliable
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regulation (≥2-fold), seven of  which were upregulated in
schwannoma cells, seven downregulated. Two were found
to be expressed at a level too low for reliable quantiﬁcation.
The regulated cDNAs include transmembrane proteins
(integrins α6, β1 and β4), proteins involved in the remod-
elling of  the extra cellular matrix (matrix metalloprotein-
ase’s MMP11 and MMP14), growth factors, growth factor
receptors and associated proteins [placental growth factor
(PGF), VEGF, p75 low-afﬁnity nerve growth facto receptor,
insulin growth factor binding protein 1 (IGFBP1)], two
tyrosine kinases (TIE1, TNK1), a cytokine (interleukin
IL11), myelin-associated glycoprotein (MAG) and prion
protein (PRNP).
Integrins α6, β1 and β4, the small GTPase Rac1 and
Jun – kinase 2 were chosen for detailed analysis of  protein
expression, kinase activity assays, immunocytochemistry,
immunohistochemistry and functional assays in separate
studies [9,19]. Because of  the established role of  merlin in
the Rac signalling pathway we further analysed protein
expression of  RhoGDI, which regulates small GTPases. As
human schwannoma cells show altered migration prop-
erties [32] and as low-afﬁnity NGF receptor is involved in
Schwann cell migration and survival [33], we also analy-
sed p75 low-afﬁnity NGF receptor expression at protein
level in primary human schwannoma and Schwann cells
by Western Blot. RhoGDI and p75 low-afﬁnity NGF recep-
tor showed no differential expression in Schwann and
schwannoma cells (Figure 1). These protein expression
data are in line with RNA data by cDNA array (RhoGDI
data are not shown in Table 2 as they were not differen-
tially expressed) and RT-PCR.
Discussion
In this work we aimed to identify differences in the mRNA
expression levels in primary Schwann cells derived either
from human schwannoma tumour biopsies or normal
nerve which might be involved in the progression of
Table 2. Genes with differential regulation between Schwann and schwannoma cells as found by array analysis
Increased Decreased
Alpha1 catenin (CTNNA1) D13866; L23805 CAS-BR-M murine ecotropic retroviral transforming sequence B 
(CBL-B) U26710
Alzheimer’s disease amyloid A4 protein precursor (APP) Y00264 c-jun N-terminal kinase 2 (JNK2) L31951
B-lymphocyte CD19 antigen precursor (CD19) M21097 Interleukin-11 (IL-11) M57765
CD44 antigen haematopoietic form precursor (CD44) M59040 Low-afﬁnity nerve growth factor receptor (NGFR) M14764
Cortiocoropin releasing factor receptor 1 precursor (CRHR1) 
X72304
Macrophage inﬂammatory protein 2 alpha (MIP2-alpha, GRO2) 
X53779
Cyclin-dependent kinase inhibitor 1 (CDKNA1A) U09579; L25610 Matrix metalloproteinase 11 (MMP11) X5776
Endothelial transcription factor GATA2 M68891 Matrix melalloproteinase 14 precursor (MMP14) D25612; X83535
Glucocorticoid receptor DNA binding factor 1 (GRFL1) M73033 Myelin-associated glycoprotein precursor (MAG) M29273
27-kDa heat-shock protein 27-kDaA (HSP27) X54079 Placenta growth factors 1 + 2 (PGF) X54936
Integrin alpha 6 precursor (ITGA6) M35198; J05522 Tyrosine kinase receptor tie-1 precursor (TIE1) X60957; S89716
Integrin beta 1 (ITGB1) X07979 High mobility group protein (HMG-I) M23619
Integrin beta 4 (ITGB4) X53587; X51841 Matrix metalloproteinase 17 (MMP17) X89576
Major prion protein precursor (PRP) M13667 Metalloproteinase inhibitor 1 precursor (TIMP1) X03124
Platelet-derived growth factor A subunit precursor (PDGFA) 
X06374
Dual speciﬁcity mitogen-activated protein kinase kinase 3 (MAP2K3) 
L36719
Prothymosin alpha (PTMA) M26708 Inhibin alpha subunit precursor (INHA) M13981
Putative transcription activator DB1 (ZNF161) D28118 Protein kinase MLK-3 (MAP3K11) L32976
Ras-related C3 botulinum toxin substrate 1; p21-rac1(RAC1) 
M29870; M31467
Vascular endothelial growth factor receptor 1 (FLT1) X51602;
U01134
Sodium- and chloride-dependent taurine transporter (SLC6A6) 
Z18956
Tyrosine kinase tnk1 (TNK1) U43408
Vascular endothelial growth factor precursor (VEGF) M32977;
M27281
G1/S-speciﬁc cyclin D1 (CCND1) X59798; M64349
ETS oncogene (PEP1) L16464
Insulin-like growth factor binding protein 1 (IGFBP1) M31145
Monocyte chemotactic protein 1 precursor (MCP1) M24545
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Schwann to schwannoma cells. Using cDNA array hybrid-
ization followed by real-time RT-PCR conﬁrmation, we
found 13 genes to be differentially expressed in schwan-
noma cells compared with Schwann cells. Most of  them
have not yet been shown to be associated with schwan-
noma, though are known to play a role in the progression
of  other tumours.
A similar study was conducted by Welling et al. [34] on
vestibular schwannoma vs. peripheral nerve tissue. They
found 42 genes to be upregulated in the majority of
tumours they investigated. Eight genes were signiﬁcantly
downregulated. Importantly there is no overlap in the
ﬁndings between the study by Welling and our own data
presented here. However, as they also state in their discus-
sion, their use of  vestibular nerve adjacent to the tumour
as a control is not ideal. Furthermore normal nerve tissue
consists of  myelinating Schwann cells attached to axons
whereas in schwannoma nonmyelinating Schwann cells
dominate. Thus, Schwann cell proteins regulated by axon
contact are upregulated in the experimental design of  that
group. We chose to investigate cultured primary cells in
order to have comparable Schwann cell differentiation
stimuli for both cell types. Using almost pure standardized
cell cultures, however, also has its drawbacks, as cells are
known to undergo changes in their expression proﬁles in
vitro. However, among the differentially expressed genes
identiﬁed by us, the genes encoding for the integrin chains
α6, β1 and β4 have been investigated in great detail by our
group. The mRNA over expression of  those in schwan-
noma cells could not only be clearly detected at protein
level using different methods as well as in tissue sections,
but did also correlate with increased adhesion to extra cel-
lular matrix [9]. Thus, these ﬁndings strongly indicate
that our experimental set-up is valuable.
Genes for which differential regulation was discovered
in our cDNA array analysis and which were not known to
Table 3. Genes with differential regulation between Schwann and 
schwannoma cells as found by real-time polymerase chain reaction
Gene Mean ± SEM Regulation in schwannoma
APP 0.74 ± 0 None
CBL-B 0.87 ± 0.15 None
CCND1 1.72 ± 0.31 None
CD19 NA NA
CDKN1A 1.55 ± 0.22 None
CTNNA1 1.28 ± 0.35 None
GRLF1 0.7 ± 0.06 None
GRO2 1.38 ± 0.31 None
HMGA 1.01 ± 0.20 None
IGFBP1 25.26 ± 8.20 Up
IL11 0.31 ± 0.06 Down
INHA 1.63 ± 0.27 None
ITGA6 8.54 ± 1.13 Up
ITGB1 9.36 ± 4.08 Up
ITGB4 185.17 ± 85.08 Up
JNK2 1.24 ± 0.12 None
MAG 0.18 ± 0.02 Down
MAP2K3 0.29 ± 0.17 Down
MAP3K11 0.64 ± 0.10 None
MCP1 1.62 ± 0.17 None
MMP11 0.27 ± 0.05 Down
MMP14 0.32 ± 0.08 Down
MMP17 0.98 ± 0.16 None
PDGFA 1.55 ± 0.06 None
PEP1 1.84 ± 0.28 None
PGF 0.53 ± 0.11 Down
PRP 2.84 ± 0.25 Up
PTMA 1.29 ± 0.30 None
P75 0.65 ± 0.09 None
RAC1 1.66 ± 0.30 None
SLC6A6 1.09 ± 0.15 None
TIE1 0.33 ± 0.04 Down
TIMP1 0.89 ± 0.13 None
TNK1 2.1 ± 0.10 Up
VEGF 3.41 ± 1.05 Up
ZNF161 1 ± 0.15 None
NA, not available.
Figure 1. Rho-GDI and p75 expression in Schwann and 
schwannoma cells. Western blot analysis of  total cell lysates (NF2–/–
= schwannoma cells; NF2+/+ = Schwann cells) after SDS-page, 
probing for Rho-GDI (A) and p75 (B).
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be regulated or expressed in Schwann cells are discussed
in more detail below.
We found MAG is downregulated in human schwan-
noma cells. MAG is a membrane protein involved in the
process of  myelination. It is expressed in differentiated
Schwann cells. Rat schwannoma cell lines express mainly
the short isoform S-MAG. Three rat schwannoma cell lines
show an inverse correlation of  MAG expression and pro-
liferation [35]. This ﬁts for our human schwannoma cells
as they present higher proliferation rates compared with
their normal counterparts [36] and MAG expression was
found to be downregulated.
The prion protein precursor gene (PRNP) coding for the
prion protein (PrP) gene is upregulated in human schw-
annoma cells. It is a ubiquitous glycoprotein expressed
strongly in neurones and its expression in mouse
Schwann cells has been described by Ford et al. [37]. As a
plasma membrane protein PrP is involved with copper
uptake, protection against oxidative stress, cell adhesion,
differentiation, signalling and survival in the central ner-
vous system. Interestingly PRNP has been found to be over
expressed in a TNF-resistant human breast carcinoma cell
line [38], thus indicating a potential role in other
tumours.
The matrix metalloproteinase’s 11 (MMP11) and 14
(MMP14) are both downregulated in schwannoma cells.
Matrix metalloproteinase’s are involved in the remodel-
ling of  the extra cellular matrix and overexpression of
MMPs is often correlated with tumour progression such as
invasive tumour growth. MMP14 but not MMP11 has
been described in the peripheral nervous system [39]. It is
of  interest that plexiform neuroﬁbromas express fewer
MMP-3 and MMP-1 than normal human Schwann cells
[40]. To understand the role of  MMP in schwannomas
other MMP’s and MMP activity need to be analysed.
Interleukin 11 (IL11), downregulated in schwannoma
cells, is an anti-inﬂammatory cytokine with multiple bio-
logical activities. It has been shown to stimulate prolifer-
ation of  human myeloma cell lines. Other than that, no
role in tumourigenesis has yet been described for this pro-
tein. Interestingly, in the setting of  peripheral nerve injury
IL11 expression is known to be increased followed by an
immediate restoration of  the basal levels [41], suggesting
a distinct function in nerve regeneration and Schwann
cell differentiation.
The gene for PGF is also downregulated in human
schwannoma cells. PGF expression has not been described
in Schwann cells before. PGF belongs to the family of  vas-
cular endothelial growth factors (VEGF) and its over
expression has accordingly been linked to tumour angio-
genesis [42]. The regulation we found is difﬁcult to inter-
pret as schwannoma cell cultures are no model for
angiogenesis and schwannomas are not highly vascular-
ized. Thus, other roles of  PGF, for example, affecting
monocyte activation, remain to be investigated in
schwannomas.
On the other hand, VEGF itself  is upregulated in human
schwannoma cells, pointing to a different role of  the two
proangiogenic factors. In addition to playing a role in
angiogenesis also in peripheral nerves [43], VEGF inﬂu-
ences differentiation of  different cell types, which includes
acting as a Schwann cell mitogen [44]. VEGF is upregu-
lated by hypoxia, which does not play a role in a cell cul-
ture system. However, not all isoform’s of  VEGF are
regulated by hypoxia [45]. Our primer pair for quantita-
tive RT-PCR is not able to distinguish between the different
isoform’s. Interestingly VEGF is expressed in schwanno-
mas and one study found a positive correlation of  VEGF
measured by ELISA and tumour growth measured by two-
dimensional MRI measurement [46].
The insulin-like growth factor binding protein 1
(IGFBP1) is strongly upregulated in schwannoma cells.
IGFBP-1 binds to the insulin-like growth factor 1 (IGF-1)
and regulates its availability increasing or decreasing it
depending on the physiological context [47]. IGF-1 has a
role in cell differentiation as wells as acts a mitogen for dif-
ferent cells including Schwann cells [48]. IGF1 is a strong
inhibitor of  apoptosis also in Schwann cells [49,50] and
promotes Schwann cell motility [51]. But, IGFP-1 also
exerts IGF-independent effects on cell growth, differentia-
tion and survival [52]. IGFBP-2 correlates with tumour
grade in gliomas [47]. IGFBP-1 has found to be expressed
in astrocytomas and meningiomas [53]. Increased IGFBP-
1 levels seem to be associated with endometrial cancer risk
in older women and women with a higher body mass
index [54]. The same authors also found a positive associ-
ation of  IGFBP-1 and ovarian cancer [55].
The expression of  the gene for tyrosine kinase with
immunoglobulin and EGF factor homology domains
(TIE1) was reduced in schwannoma cells. This is the ﬁrst
time that TIE 1 is described in Schwann cells. This endot-
helial surface receptor with kinase activity is involved in
vascular development and probably in cell adhesion to the
vascular endothelium. It has been found to be over
expressed in various cancers, where it was shown to acti-
vate Akt via PI3-kinase to inhibit apoptosis [56]. This role
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could be true in schwannoma as well as we recently
described reduced apoptosis rates in primary human
schwannoma cells [57].
Tyrosine kinase, nonreceptor 1 (TNK1) is upregulated
in schwannoma cells, this being the ﬁrst description of
TNK1 in Schwann cells. TNK1 was ﬁrst identiﬁed in
haematopoietic stem cells and binds to phospholipase C-
gamma 1, suggesting a role in phospholipid signal trans-
duction [58]. Beside this, little is yet known about this
protein.
Regarding the MAP kinase pathways in Schwann cells
most papers deal with the MEK1/2 Erk1/2 pathway, while
MEK3 has not been studied in Schwann cells. However,
inhibition of  p38 MAP-kinase downstream of  MEK3
results in reduced apoptosis of  Schwann cells in vivo [59]
and decreased myelination [60], suggesting that the
MEK3/p38 pathway could be relevant in schwannomas.
Holtkamp et al. 2004 [61] investigated the differential
gene expression of  other tumours originating from periph-
eral nerves, such as benign dermal and plexiform neuroﬁ-
bromas and malignant peripheral nerve sheath tumours
(MPNST) of  neuroﬁbromatosis type 1 (NF1) patients. Der-
mal neuroﬁbromas originate from Schwann cells affected
by a second hit in the tumour suppressor gene NF1, and
MPNSTs originate from plexiform neuroﬁbromas, thereby
presenting an interesting model of  tumour progression.
They found clear differences in gene expression between
all three tumour types, being most prominent when com-
paring dermal neuroﬁbromas and MPNSTs. Two of  the
genes differentially expressed in those tumours were also
identiﬁed by us in the study of  Schwann and NF2 schw-
annoma cells. Integrin α6 (ITGA6) and prion protein
(PRNP) are highly expressed in dermal neuroﬁbromas,
but downregulated in MPNSTs, expression in plexiform
neuroﬁbromas being in between. Unfortunately, Holt-
kamp et al. did not compare the tumour samples to normal
controls, so the basal expression level of  ITGA6 and PRNP
is unknown.
Differentially regulated genes and genes not previously
known to be expressed by Schwann cells identiﬁed in the
here presented study certainly need to be investigated in
greater detail, including protein expression levels, kinase
activities and analysis of  the functional relevance in suit-
able read outs. This work is currently under way in our
group. However, detailed biochemical assays in the in vitro
model of  human Schwann and schwannoma cells, is dif-
ﬁcult due to limited access to biopsy material. Moreover
primary human Schwann and schwannoma cell cultures
show a limited lifespan of  5–6 weeks. Even though real-
time PCR is a far more sensitive method than cDNA array
hybridization, even here the low amount of  RNA available
led to a higher variation than expected. A similarly sensi-
tive method for the measurement of  protein amounts is
not yet available. However, it is important to note that the
validity of  our model has been proved by following-up on
the integrin expression data [9], indicating a role for Rac1
in schwannoma [19], and by showing corresponding pro-
tein expression levels of  RhoGDI and p75 protein in this
paper.
In conclusion, we have identiﬁed a number of  novel
candidate genes with differential regulation in primary
human Schwann and schwannoma cells, some of  which
were yet not known to be expressed by Schwann cells.
Further studies will have to show their relevance for
schwannoma formation.
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